FASN and cancer: Importantly, disease-free survival was significantly reduced in cases of combined ATF6 and FASN amp/gain compared to those showing ATF6-only amp/gain in the Pan-Cancer Atlas (P = 0.0394), with a trend observed in the TCGA database (P = 0.4046; Extended Data Fig. 3e,f).